Description: Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Home Page: www.tevapharm.com
124 Dvora HaNevi’a Street
Tel Aviv,
6944020
Israel
Phone:
972 3 914 8213
Officers
| Name | Title |
|---|---|
| Mr. Richard D. Francis | President, CEO & Director |
| Mr. Eliyahu Sharon Kalif | Executive VP & CFO |
| Mr. Mark Sabag | Executive Vice President of International Markets Commercial |
| Mr. Richard Gordon Daniell | Executive Vice President of European Commercial |
| Mr. Matthew Shields | Executive Vice President of Global Operations |
| Mr. Amir Weiss | Senior VP & Chief Accounting Officer |
| Mr. Ran Meir | Head of Investor Relations |
| Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer |
| Mr. David R. Mcavoy J.D. | Executive VP & Chief Legal Officer |
| Mr. Placid Jover | Executive VP & CHRO |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 6.1614 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.1768 |
| Price-to-Sales TTM: | 1.1622 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 37000 |